2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1629

Functional Effect Of NR1H3 (LXRA) Promoter Polymorphisms In Korean Patients With Systemic Lupus Erythematosus
Abstract Number: 2347

Functional Single Nucleotide Polymorphisms In The Interferon-γ and The NLRP3 (Cryopyrin) Genes Associated With Anti-TNF Response In Danish Rheumatoid Arthritis Patients
Abstract Number: 2492

Functionally Distinct ERAP1 Haplotype Combinations Distinguish Individuals With Ankylosing Spondylitis
Abstract Number: 1853

Functions Of Aminopeptidase N/CD13 In Vitro On Rheumatoid Arthritis Synovial Cells
Abstract Number: 864

Further Reduction In Nonvertebral Fracture Rate Is Observed Following 3 Years Of Denosumab Treatment: Results With Up To 7 Years In The Freedom Extension
Abstract Number: 2904

Gadolinium-Based Compounds Induce NLRP3-Dependent IL-1β Production and Peritoneal Inflammation
Abstract Number: 2205

Galectin-3 and Transforming Growth Factor-β Signaling In The Pathogenesis Of Coronary Artery Aneurysms In Kawasaki Disease
Abstract Number: 630

Galectin-3-Binding Protein Is Highly Increased On Circulating Microparticles In SLE Patients and Co-Localizes With IgG In Glomerular Deposits In Human Lupus Nephritis
Abstract Number: 1445

GEMS Audit: An Evaluation Of Routine Use Of Subcutaneous Methotrexate In Rheumatoid Arthritis
Abstract Number: 598

Gender Influence On Lupus Nephritis Outcomes In An Urban, Multiethnic Population
Abstract Number: 2012

Gender Influences On Organ Manifestations In a New Orleans Sarcoidosis Population
Abstract Number: 1767

Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Abstract Number: 1904

Gene Expression In Whole Blood Predicts The Abatacept–Methotrexate Combination Responsiveness In Rheumatoid Arthritis: Preliminary Results From The Power Doppler Ultrasonography IM101-179 Study
Abstract Number: 1488

Gene Expression Profile According To Systemic Disease Activity In Primary Sjögren’s Syndrome: Results From The Assessment Of Systemic Signs and Evolution Of Primary Sjögren’s Syndrome (ASSESS) Cohort
Abstract Number: 2865

Gene Expression Profiles Of Fibroblast-Like Synoviocytes In Early Stage Of Oligoarticular Juvenile Idiopathic Arthritis Are Different In Extended Versus Persistent Course

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].